“Comparing The Safety And Efficacy Of Sitagliptin Vs Dapagliflozin And The Risk Of Hyperkalaemia Among People With Type 2 Diabetes Mellitus And Kidney Disease ” (2025) Vascular and Endovascular Review, 8(9s), pp. 230–236. doi:10.64149/J.Ver.8.9s.230-236.